Domača stranBNTX • NASDAQ
add
BioNTech
112,78 $
Po zaprtju:(0,00 %)0,00
112,78 $
Konec trgovanja: 13. avg., 16:05:07 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
111,00 $
Dnevni razpon
111,50 $ - 113,39 $
Letni razpon
81,20 $ - 131,49 $
Tržna kapitalizacija
27,06 mrd. USD
Povprečni obseg
683,86 tis.
Razm. P/E
-
Dividendna donosnost
-
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | jun. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 260,80 mio. | 102,64 % |
Stroški poslovanja | 621,10 mio. | −39,74 % |
Čisti dohodek | −386,60 mio. | 52,14 % |
Čista dobičkovnost prihodkov | −148,24 | 76,38 % |
Earnings per share | −1,60 | 52,38 % |
EBITDA | −385,70 mio. | 57,70 % |
Efektivna davčna stopnja | 4,00 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | jun. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 14,04 mrd. | −18,84 % |
Skupna sredstva | 21,64 mrd. | −2,70 % |
Skupne obveznosti | 3,13 mrd. | −1,05 % |
Celoten lastniški kapital | 18,51 mrd. | — |
Shares outstanding | 240,40 mio. | — |
Razmerje P/B | 1,44 | — |
Donosnost sredstev | −5,10 % | — |
Donosnost kapitala | −5,75 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | jun. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −386,60 mio. | 52,14 % |
Denar iz dejavnosti | 146,50 mio. | −91,00 % |
Denar iz naložb | −64,40 mio. | 73,32 % |
Denar iz financiranja | −13,30 mio. | 41,92 % |
Neto sprememba denarnih sredstev | 84,60 mio. | −93,96 % |
Prost denarni tok | −292,96 mio. | −116,69 % |
Vizitka
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
6.772
